[go: up one dir, main page]

PE20151494A1 - Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer - Google Patents

Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer

Info

Publication number
PE20151494A1
PE20151494A1 PE2015000485A PE2015000485A PE20151494A1 PE 20151494 A1 PE20151494 A1 PE 20151494A1 PE 2015000485 A PE2015000485 A PE 2015000485A PE 2015000485 A PE2015000485 A PE 2015000485A PE 20151494 A1 PE20151494 A1 PE 20151494A1
Authority
PE
Peru
Prior art keywords
cancer
elaboration
compounds
treatment
novel process
Prior art date
Application number
PE2015000485A
Other languages
English (en)
Inventor
Sriram Naganathan
Nathan Guz
Matthew Pfeiffer
Gregory C Sowell
Tracy Bostick
Jason Yang
Amit Srivastava
Original Assignee
Exelixis Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Genentech Inc filed Critical Exelixis Inc
Publication of PE20151494A1 publication Critical patent/PE20151494A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Referida a un proceso para elaborar un compuesto de la formula (I), que comprende poner en contacto un compuesto de formula (II-1) con un compuesto de formula (IIa-1). El compuesto de formula (I) es un inhibidor de MEK y puede usarse para tratar el cancer
PE2015000485A 2012-10-12 2013-10-14 Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer PE20151494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
PE20151494A1 true PE20151494A1 (es) 2015-11-06

Family

ID=49474740

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2019002024A PE20191818A1 (es) 2012-10-12 2013-10-14 Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol
PE2015000485A PE20151494A1 (es) 2012-10-12 2013-10-14 Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
PE2019001563A PE20200387A1 (es) 2012-10-12 2019-08-08 Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2019002024A PE20191818A1 (es) 2012-10-12 2013-10-14 Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2019001563A PE20200387A1 (es) 2012-10-12 2019-08-08 Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer

Country Status (31)

Country Link
US (4) US9771347B2 (es)
EP (1) EP2909188B1 (es)
JP (2) JP6300042B2 (es)
KR (1) KR102204520B1 (es)
CN (2) CN104837826B (es)
AU (1) AU2013328929B2 (es)
BR (1) BR112015008113B1 (es)
CA (1) CA2889466C (es)
CL (1) CL2015000926A1 (es)
CR (2) CR20200237A (es)
EA (1) EA030613B1 (es)
ES (1) ES2671502T3 (es)
GE (1) GEP201706690B (es)
HK (1) HK1213567A1 (es)
HR (1) HRP20180670T1 (es)
IL (1) IL238116B (es)
IN (1) IN2015DN03928A (es)
MA (1) MA38085B1 (es)
MX (2) MX372708B (es)
MY (1) MY186549A (es)
NZ (1) NZ706723A (es)
PE (3) PE20191818A1 (es)
PH (1) PH12015500785B1 (es)
PL (1) PL2909188T3 (es)
SA (1) SA515360271B1 (es)
SG (1) SG11201502795VA (es)
SI (1) SI2909188T1 (es)
TR (1) TR201807861T4 (es)
UA (1) UA115455C2 (es)
WO (1) WO2014059422A1 (es)
ZA (1) ZA201502349B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104837826B (zh) 2012-10-12 2018-07-27 埃克塞里艾克西斯公司 制备用于治疗癌症的化合物的新型方法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
JP6914202B2 (ja) 2015-06-30 2021-08-04 ジェネンテック， インコーポレイテッド 薬物を含有する即放性錠剤及び錠剤の形成プロセス
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
BR112019002036A2 (pt) 2016-08-12 2019-05-14 Genentech Inc métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal
KR20190061030A (ko) 2016-09-29 2019-06-04 제넨테크, 인크. Mek 억제제, pd-1 축 억제제 및 탁산을 사용한 조합 요법
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
JP2024509269A (ja) 2021-03-09 2024-02-29 ジェネンテック， インコーポレイテッド 脳がんの治療における使用のためのベルバラフェニブ
US20240366609A1 (en) 2021-04-06 2024-11-07 Genentech, Inc. Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
EP0754684A4 (en) 1994-04-01 1998-05-13 Shionogi & Co OXIME DERIVATIVES AND BACTERICIDE CONTAINING IT AS ACTIVE INGREDIENTS
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (en) 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
HUP0003731A3 (en) 1997-07-01 2002-11-28 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
EP0993437B1 (en) * 1997-07-01 2006-11-08 Warner-Lambert Company Llc 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
HUP0104607A3 (en) 1998-12-15 2002-12-28 Warner Lambert Co Use of a mek inhibitor for preventing transplant rejection
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
NZ512859A (en) 1998-12-22 2004-06-25 Warner Lambert Co Combination chemotherapy
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
CA2358438A1 (en) 1999-01-07 2000-07-13 David Thomas Dudley Antiviral method using mek inhibitors
WO2000040235A2 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Treatment of asthma with mek inhibitors
AU2483400A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 4'heteroaryl diarylamines
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
BR9916896A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Diaril aminas substituìdas com 1-heterociclo
AU2201500A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
DE69926800T2 (de) 1999-01-13 2006-05-18 Warner-Lambert Company Llc Benzoheterozyklen und ihre verwendung als mek inhibitoren
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
EP1202724B1 (en) 1999-07-16 2003-10-01 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
WO2001005390A2 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
IL147619A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
IL155155A0 (en) 1999-09-17 2003-10-31 Cor Therapeutics Inc BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
EA200300187A1 (ru) * 2000-08-25 2003-08-28 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си Способ получения n-арилантраниловых кислот и их производных
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
EP1439836A1 (en) 2001-10-31 2004-07-28 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PA8569301A1 (es) 2002-03-13 2004-10-08 Array Biopharma Inc "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimidazole derivatives as mek inhibitors"
KR20040098013A (ko) 2002-03-13 2004-11-18 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화된 벤즈이미다졸 유도체
US7314873B2 (en) 2002-06-11 2008-01-01 Merck & Co., Inc. (Halo-benzo carbonyl)heterobi cyclic p38 linase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
JP4617299B2 (ja) 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EA010297B1 (ru) 2003-06-20 2008-08-29 ЮСиБи ФАРМА С.А. Производные тиенопиридона как ингибиторы киназ
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005009975A2 (en) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
JP4931419B2 (ja) 2003-09-19 2012-05-16 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
BRPI0416692A (pt) 2003-11-19 2007-01-30 Array Biopharma Inc inibidores heterocìclicos de mek e métodos de emprego destes
EP1694673B1 (en) 2003-12-08 2008-01-16 F.Hoffmann-La Roche Ag Thiazole derivates
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
US7956191B2 (en) * 2004-10-20 2011-06-07 Merck Serono Sa 3-arylamino pyridine derivatives
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
CN111643496A (zh) 2006-12-14 2020-09-11 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
CN104837826B (zh) 2012-10-12 2018-07-27 埃克塞里艾克西斯公司 制备用于治疗癌症的化合物的新型方法
DK3103789T3 (en) 2014-02-07 2019-01-28 Sumitomo Chemical Co METHOD FOR PREPARING (R) -1,1,3-TRIMETHYL-4-AMINOINDAN
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
CL2015000926A1 (es) 2015-08-28
WO2014059422A1 (en) 2014-04-17
AU2013328929A1 (en) 2015-04-30
ZA201502349B (en) 2019-12-18
SA515360271B1 (ar) 2016-05-19
US20200392104A1 (en) 2020-12-17
CN104837826A (zh) 2015-08-12
PH12015500785A1 (en) 2015-06-15
EA201590700A1 (ru) 2015-09-30
NZ706723A (en) 2018-07-27
ES2671502T3 (es) 2018-06-06
PE20191818A1 (es) 2019-12-27
SI2909188T1 (en) 2018-07-31
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
GEP201706690B (en) 2017-06-26
MX372708B (es) 2020-05-29
US10793541B2 (en) 2020-10-06
CN108948043A (zh) 2018-12-07
MA38085A1 (fr) 2018-08-31
MX2020005533A (es) 2020-10-12
PE20200387A1 (es) 2020-02-24
CA2889466A1 (en) 2014-04-17
HRP20180670T1 (hr) 2018-07-13
US10239858B2 (en) 2019-03-26
TR201807861T4 (tr) 2018-06-21
IL238116B (en) 2018-06-28
US11414396B2 (en) 2022-08-16
EP2909188A1 (en) 2015-08-26
CN108948043B (zh) 2021-05-04
JP6300042B2 (ja) 2018-03-28
IN2015DN03928A (es) 2015-10-02
JP2015533175A (ja) 2015-11-19
PH12015500785B1 (en) 2015-06-15
CA2889466C (en) 2021-09-14
UA115455C2 (uk) 2017-11-10
SG11201502795VA (en) 2015-05-28
HK1213567A1 (zh) 2016-07-08
US9771347B2 (en) 2017-09-26
BR112015008113A2 (pt) 2017-07-04
AU2013328929B2 (en) 2018-01-04
KR102204520B1 (ko) 2021-01-20
EP2909188B1 (en) 2018-03-07
US20170349569A1 (en) 2017-12-07
JP2018052973A (ja) 2018-04-05
CR20200237A (es) 2020-07-26
MY186549A (en) 2021-07-26
US20150210668A1 (en) 2015-07-30
CN104837826B (zh) 2018-07-27
MX2015004660A (es) 2015-08-07
PL2909188T3 (pl) 2018-08-31
EA030613B1 (ru) 2018-08-31
BR112015008113B1 (pt) 2022-05-24
KR20150067339A (ko) 2015-06-17
HK1213878A1 (en) 2016-07-15
CR20150245A (es) 2015-11-19

Similar Documents

Publication Publication Date Title
PE20151494A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
NI201900019A (es) Inhibidores de procesos metabólicos celulares
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX2014001218A (es) Tratamiento de cancer de mama.
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20130550A (es) Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina
MX387487B (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton.
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
EA201301130A1 (ru) Имидазопиридазины в качестве ингибиторов акт киназы
BR112015018249A2 (pt) agente de tratamento, método de tratamento de uma chapa de aço, chapa de aço tratada e processo para a produção de uma chapa de aço tratada
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
BR112015005369A2 (pt) inibidores de usp30 e métodos para sua utilização
AR097882A1 (es) Método para procesar la biomasa que contiene celulosa
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
GB201316955D0 (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
UY33942A (es) Derivados tópicos de piridil/pirazinil metilenoxi como inhibidores de la tirosina cinasa del bazo
NI201400020A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CL2012003201A1 (es) Metodo para tratar una cdi en un mamifero que esta siendo sometido simultaneamente a una terapia con antibioticos para combatir una infeccion diferente, que comprende el uso de fidaxomicina.
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
PE20142020A1 (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
CL2011000273A1 (es) Uso de un inhibidor de la enzima fosfohidrolasa de acido fosfatidico (pap) o combinacion de inhibidores, en que el inhibidor es d(+) propranolol, y la combinacion es mezcla racemica de propranolol o d(+) propranolol junto con desipramina, para preparar un medicamento util en el tratamiento del cancer.

Legal Events

Date Code Title Description
FG Grant, registration